Healthcare and pharmaceutical firms reported notable operational and strategic progress, led by positive clinical data from Cue Biopharma and Beacon Therapeutics. Telix Pharmaceuticals expanded its radiopharmaceutical pipeline through a $1.65 billion acquisition of ITM Isotope Technologies. Meanwhile, Chinese biopharma shares surged on expectations that US licensing deals will remain permitted.
Outperforming an established biologic comparator positions Cue's licensed immunology asset to de-risk its pivotal transition while validating its strategic pivot away from oncology.
Cue Biopharma cleared a mid-stage trial for its chronic spontaneous urticaria candidate CUE-221, marking the biotech's first clinical data since shifting its focus from into immunology. The placebo-controlled trial enrolled 145 subjects in China who received one of three doses of CUE-221, a placebo, or a comparator arm of Novartis and Roche drug Xolair. At Week 12, hives resolved completely in 43% to 54% of patients across the CUE-221 cohorts, compared to 11% for the placebo group and 41% for the Xolair arm. CUE-221 responses deepened through Week 22 before widening further against Xolair by Week 28, when the high dose achieved a 60% response rate against 24% for Xolair. Cue paid Ascendant Health Sciences $15 million in April for ex-China rights to the and plans to advance CUE-221 into a phase 2b/3 trial.
Week 12 Hives Resolution Rate (%)
CUE-221 cohorts achieved higher resolution rates than placebo and Xolair.
Beacon Therapeutics Gene Therapy Succeeds in Pivotal XLRP Trial
Clearing low-light vision endpoints where pharma majors failed proves targeted ocular gene therapy developers can solve vector efficacy hurdles that defeated heavily capitalized competitors.
Beacon Therapeutics succeeded in a pivotal trial for its gene therapy targeting X-linked retinitis pigmentosa, clearing a hurdle where larger competitors like Johnson & Johnson and Biogen stumbled. The phase 2/3 Vista study tested laruparetigene zovaparvovec in 85 men and boys, evaluating two dose levels against a control group over 12 months. No patients in the control group met the responder definition of reading 15 more letters on a low-light eye chart. In contrast, 24.1% of patients in the low-dose group and 31% of patients in the high-dose group achieved the primary endpoint. Beacon plans to initiate a rolling license application to the before the end of the year, alongside seeking approvals in the European Union and the U.K.
Radiopharma Companies Merge Following Unexpected FDA Rejection
Vertical integration between radiopharma developers and isotope manufacturers insulates commercialization from supply bottlenecks, converting volatile raw-material sourcing risks into internal operating margins.
Telix Pharmaceuticals has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for $1.65 billion on a cash-free and -free basis. Under the terms of the transaction, ITM shareholders will receive approximately $1.25 billion in Telix shares priced at $11.84 each, alongside an additional $700 million in contingent consideration tied to regulatory and commercial milestones for the drug candidate ITM-11. Telix will also assume $302 million of net debt at closing. The deal combines Telix's commercial precision medicine platform with ITM's radioisotope manufacturing business, which generated $273 million in in 2025. Upon completion, existing Telix shareholders will own 76.3 percent of the combined company, leaving ITM holders with a 23.7 percent stake. The is expected to close by the end of fiscal 2026, subject to approval by Telix shareholders.
Bob Langer and Yann LeCun Join Board of Cellular Intelligence
Combining LeCun's pattern-recognition architectures with Langer's drug-delivery pedigree signals a shift toward deploying fundamental AI researchers directly onto biological board seats to derisk acquired clinical assets.
According to fortune.com, Cellular Intelligence appointed Moderna co-founder Robert Langer and researcher Yann LeCun to its scientific advisory board to guide the development of AI models for predicting cellular behavior. Langer also joined the board of directors as an observer, alongside Jens Nielsen and Fabian Theis. The Boston-based company aims to apply pattern-recognition systems to biology to accelerate drug development, following its of global rights to the Phase 2-ready Parkinson's disease cell therapy STEM-PD from Novo Nordisk in May. Novo Nordisk took an stake in Cellular Intelligence as part of the transaction and remains eligible for future milestones and royalties. Cellular Intelligence, formerly known as Somite.ai and founded in 2023, has raised more than $70 million from investors including Khosla Ventures, the Chan Zuckerberg Initiative, and Novo Nordisk.
Chinese Biopharma Stocks Jump as US Weighs Keeping Door Open to Drug Deals
Carving out therapeutic licensing from national security export controls preserves cross-border royalty pipelines while isolating biotech from the broader U.S.-China technology decoupling.
Chinese biopharma stocks jumped in Hong Kong on Monday after cnbc.com reported that the U.S. Department is drafting rules that would allow American drugmakers to continue licensing most treatments from Chinese firms. Innovent jumped 6 percent, Akeso surged 8 percent, and CSPC Pharmaceutical Group gained more than 6 percent. HUTCHMED climbed 3 percent and Sino Biopharmaceutical added 8 percent, pushing the Hang Seng Biotech up more than 5 percent. The proposed rules would likely permit U.S. investments in promising Chinese drugs while excluding technologies related to pathogens or biotechnology that could be weaponized. That approach separates biopharma from sectors like and , where Washington has tightened restrictions. Pfizer announced a partnership worth up to $10.5 billion with Innovent in May covering 12 programs. GlobalData figures cited by Reuters show that almost half of U.S. foreign drug licensing deals in 2025 involved Chinese companies. Nomura data indicates that a record 81 deals worth a combined $110 billion were completed in the first half of 2026.
Cardinal Health Outlines Growth in Specialty and At-Home Investments
Anchoring growth in specialty MSOs and automated small-parcel at-home logistics pivots pharmaceutical wholesalers from low-margin volume distribution toward defensible, higher-margin care management.
Cardinal Health expects fiscal 2027 adjusted -per-share to grow 13% to 15% as operating momentum normalizes following an outsized fiscal 2026. CEO Jason Hollar outlined the at recent investor conferences, pointing to operating-income expansion across the company's three reporting segments and five operating businesses. Fiscal 2026 results benefited from broad strength, including a 25% surge in the specialty business, higher healthcare utilization, and new customer onboarding. Growth in fiscal 2027 will rely on lower interest expense, a slightly higher tax rate, and $1 billion in planned share repurchases. The company is actively expanding its footprint in specialty platforms like , urology, and gastroenterology through bolt-on and managed-services organizations. At the same time, Cardinal Health is building out automated small-parcel distribution centers for higher-value at-home products, anchored by closed deals like Strive Medical and pending transactions such as AdaptHealth's diabetes business.
Walmart Partners With SCAN Health Plan to Launch Medicare Advantage Plans
Combining retail transaction data with health plan benefits leverages everyday consumer purchasing history to lower care costs and lock in long-term pharmacy footprint dominance.
Walmart and SCAN Health Plan announced a partnership on Wednesday to launch co-branded Advantage plans across two states, targeting a pool of more than two million Medicare enrollees. The offering integrates pharmacy, vision, food assistance, and over-the-counter benefits with Walmart's health ecosystem, pending regulatory approval. Members gain access to Everyday Health Signals, an platform that generates personalized nutrition and wellness from user shopping preferences and stated health goals. SCAN operates a health plan serving nearly 460,000 members across 33 counties, while Walmart brings a decade of in-store insurance experience and its licensed agency established in 2020. Financial terms of the collaboration were not disclosed.
Strong late-stage trial results, major acquisitions, and strategic AI partnerships show robust sector momentum. However, whether US regulatory clarity on Chinese licensing will hold and support sustained valuation gains across global biopharma markets remains unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.